[(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol

C114H164ClN3O21 — CID 165079773

About [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol

[(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol (PubChem CID 165079773) has the molecular formula C114H164ClN3O21 and a molecular weight of 1948.02 g/mol. Its IUPAC name is [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol.

Molecular Properties

• Compound Name: [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol
• PubChem CID: 165079773
• Molecular Formula: C114H164ClN3O21
• Molecular Weight: 1948.02 g/mol
• Exact Mass: 1946.15
• IUPAC Name: [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol
• SMILES: C=C[C@]1(C)C[C@@H](O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O.C=C[C@]1(C)C[C@@H](O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1OC(C)=O.C=C[C@]1(C)C[C@@H](OC(=O)CO)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)C1=O.C=C[C@]1(C)C[C@H]2C3(C)O[C@]4(O)CC[C@@]5(CCC3C)[C@@H](C)[C@H]1[C@]254.C[C@@H]1CC[C@@]23C[C@H](O)C(=O)[C@@]2(O)[C@]1(C)[C@H](OC(=O)CCl)CC(C1=CCn2c(=O)n(-c4ccccc4)c(=O)n2C1)[C@@H]3C
• InChI: InChI=1S/C30H36ClN3O7.C22H32O5.C22H34O4.C20H32O3.C20H30O2/c1-17-9-11-29-14-22(35)25(37)30(29,40)28(17,3)23(41-24(36)15-31)13-21(18(29)2)19-10-12-32-26(38)34(27(39)33(32)16-19)20-7-5-4-6-8-20;1-6-20(4)11-16(27-17(25)12-23)21(5)13(2)7-9-22(14(3)19(20)26)10-8-15(24)18(21)22;1-7-20(5)12-17(25)21(6)13(2)8-10-22(11-9-16(24)18(21)22)14(3)19(20)26-15(4)23;1-6-18(4)11-15(22)19(5)12(2)7-9-20(13(3)17(18)23)10-8-14(21)16(19)20;1-6-16(4)11-14-17(5)12(2)7-8-18-9-10-19(21,22-17)20(14,18)15(16)13(18)3/h4-8,10,17-18,21-23,35,40H,9,11-16H2,1-3H3;6,13-14,16,18,23H,1,7-12H2,2-5H3;7,13-14,17-19,25H,1,8-12H2,2-6H3;6,12-13,15-17,22-23H,1,7-11H2,2-5H3;6,12-15,21H,1,7-11H2,2-5H3/t17-,18+,21?,22+,23-,28+,29+,30-;13-,14+,16-,18+,20-,21+,22+;13-,14+,17-,18+,19+,20-,21+,22+;12-,13+,15-,16+,17+,18-,19+,20+;12?,13-,14-,15+,16+,17?,18-,19+,20+/m11110/s1
• InChIKey: UXSLDZOJCILTGX-IDUSFVATSA-N
• XLogP: 16.52
• TPSA: 364.02 Ų
• H-Bond Donors: 7
• H-Bond Acceptors: 24
• Rotatable Bonds: 11
• Heavy Atoms: 139
• Complexity: —

Lipinski Rule of Five

4 violations

Rule	Value
MW ≤ 500	1948.02
LogP ≤ 5	16.52
H-Bond Donors ≤ 5	7
H-Bond Acceptors ≤ 10	24

Computed Properties (RDKit)

• Structural Alerts: {'alert_name': '>_2_ester_groups', 'substructure': 'N/A'}, {'alert_name': 'alkyl_halide', 'substructure': 'N/A'}, {'alert_name': 'isolated_alkene', 'substructure': 'N/A'}

Frequently Asked Questions

What is the IUPAC name of [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol?

The IUPAC name of [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol (CID 165079773) is [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol.

What is the SMILES notation for [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol?

The canonical SMILES for [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol is C=C[C@]1(C)C[C@@H](O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O.C=C[C@]1(C)C[C@@H](O)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1OC(C)=O.C=C[C@]1(C)C[C@@H](OC(=O)CO)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)C1=O.C=C[C@]1(C)C[C@H]2C3(C)O[C@]4(O)CC[C@@]5(CCC3C)[C@@H](C)[C@H]1[C@]254.C[C@@H]1CC[C@@]23C[C@H](O)C(=O)[C@@]2(O)[C@]1(C)[C@H](OC(=O)CCl)CC(C1=CCn2c(=O)n(-c4ccccc4)c(=O)n2C1)[C@@H]3C.

What is the InChIKey of [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol?

The InChIKey is UXSLDZOJCILTGX-IDUSFVATSA-N. The full InChI is InChI=1S/C30H36ClN3O7.C22H32O5.C22H34O4.C20H32O3.C20H30O2/c1-17-9-11-29-14-22(35)25(37)30(29,40)28(17,3)23(41-24(36)15-31)13-21(18(29)2)19-10-12-32-26(38)34(27(39)33(32)16-19)20-7-5-4-6-8-20;1-6-20(4)11-16(27-17(25)12-23)21(5)13(2)7-9-22(14(3)19(20)26)10-8-15(24)18(21)22;1-7-20(5)12-17(25)21(6)13(2)8-10-22(11-9-16(24)18(21)22)14(3)19(20)26-15(4)23;1-6-18(4)11-15(22)19(5)12(2)7-9-20(13(3)17(18)23)10-8-14(21)16(19)20;1-6-16(4)11-14-17(5)12(2)7-8-18-9-10-19(21,22-17)20(14,18)15(16)13(18)3/h4-8,10,17-18,21-23,35,40H,9,11-16H2,1-3H3;6,13-14,16,18,23H,1,7-12H2,2-5H3;7,13-14,17-19,25H,1,8-12H2,2-6H3;6,12-13,15-17,22-23H,1,7-11H2,2-5H3;6,12-15,21H,1,7-11H2,2-5H3/t17-,18+,21?,22+,23-,28+,29+,30-;13-,14+,16-,18+,20-,21+,22+;13-,14+,17-,18+,19+,20-,21+,22+;12-,13+,15-,16+,17+,18-,19+,20+;12?,13-,14-,15+,16+,17?,18-,19+,20+/m11110/s1.

What are the key properties of [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol?

[(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol has a molecular weight of 1948.02 g/mol, XLogP of 16.52, 11 rotatable bonds, 7 hydrogen bond donors, and 24 hydrogen bond acceptors.

Where does this data come from?

All data for [(1S,3S,5S,6S,7R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate;(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-3,6-dihydroxy-2,4,7,14-tetramethyltricyclo[5.4.3.01,8]tetradecan-9-one;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-ethenyl-6-hydroxy-2,4,7,14-tetramethyl-9-oxo-3-tricyclo[5.4.3.01,8]tetradecanyl] acetate;[(1S,2R,4S,6R,7R,8R,14R)-4-ethenyl-2,4,7,14-tetramethyl-3,9-dioxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-hydroxyacetate;(1S,2S,3R,4S,6R,7S,8R)-4-ethenyl-2,4,10,11-tetramethyl-9-oxapentacyclo[6.5.2.01,7.03,7.06,10]pentadecan-8-ol is sourced from PubChem (CID 165079773), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).